{"doi":"10.1136/bmj.330.7488.377","title":"The treatment of lupus nephritis","abstract":null,"journal":"BMJ","year":2005,"id":596938,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1528997,"name":"Graham R V Hughes","orcid":null,"position":1,"is_corresponding":false},{"id":1528996,"name":"David P D'Cruz","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The treatment of lupus nephritis","abstract":"1918-9, for example, killed an estimated 40-50 million people. Research into influenza, in relation to its catastrophic potential, is underfunded. Worse still, we do not even seem able to provide sufficient vaccine to control epidemic influenza in the most developed countries. Little confidence exists that we could undertake a global immunisation programme for an influenza pandemic even if we had sufficient warning of its antigenic profile unless we can sharpen up on manufacture and distribution. Other notable examples of neglected diseases afflicting the world include antibacterial drug resistance, chronic obstructive pulmonary disease, alcoholic liver disease, and stroke. This is not a criticism but a fact, for the pharmaceutical industry is a business and needs to provide its shareholders with a return on their investment. Many neglected diseases are unlikely to to do this and investment represents a great commercial risk. The industry will continue to play a major part in the discovery and development of drugs; but we need much greater pluralism in both the funding and discovery of novel treatments.","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"15718519","pmcid":"PMC549098","openalex_id":"https://openalex.org/W2151036300","authors":[],"funders":[],"total_grants":0,"fwci":0.5569,"citation_percentile":0.68050552,"influential_citations":0,"citation_trend":[{"year":2015,"count":1},{"year":2016,"count":1}],"oa_status":"bronze","license":"http://www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html","oa_locations":[{"url":"https://www.bmj.com/content/bmj/330/7488/377.full.pdf","host_type":"journal"},{"url":"https://www.bmj.com/content/bmj/330/7488/377.full.pdf","host_type":"publisher"},{"url":"http://data.bmj.org/tdm/10.1136/bmj.330.7488.377","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1136/bmj.330.7488.377","host_type":"publisher"},{"url":"https://doi.org/10.1136/bmj.330.7488.377","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/15718519","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/549098","host_type":"repository"}],"fields_of_study":["Systemic Lupus Erythematosus Research","Renal Diseases and Glomerulopathies","Inflammatory Bowel Disease","Anti-Inflammatory Agents, Non-Steroidal","Antibodies, Monoclonal","Antibodies, Monoclonal, Murine-Derived","Cyclophosphamide","Humans","Immunoglobulins, Intravenous","Lupus Nephritis","Mycophenolic Acid","Rituximab"],"mesh_terms":["Rituximab","Anti-Inflammatory Agents, Non-Steroidal","Antibodies, Monoclonal","Cyclophosphamide","Humans","Lupus Nephritis","Mycophenolic Acid","Immunoglobulins, Intravenous","Antibodies, Monoclonal, Murine-Derived"],"keywords":["Lupus nephritis","Cyclophosphamide","Medicine","Systemic lupus erythematosus","Regimen","Dose","Adverse effect","Nephritis","Internal medicine","Chemotherapy","Disease"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T11:46:41.094878Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}